Cipla Faces USFDA Form 483 at Pithampur Facility – 7 Observations
NEWZA Editorial Team••Source: MoneyControl
NEWZAFinancial Intelligence Feed
⚡ Key Financial Takeaways
USFDA issued Form 483 to Cipla with 7 inspectional observations after a cGMP inspection of its Pithampur plant (Aug 17‑25, 2026).
The observations highlight potential violations of the Food, Drug and Cosmetic Act, though specific details were not disclosed.
Cipla has pledged to work closely with USFDA and remediate all issues within the stipulated timeframe.
USFDA Inspection at Pithampur The US Food and Drug Administration (USFDA) conducted a follow‑up current Good Manufacturing Practices (cGMP) inspection at Cipla’s Pithampur facility from 17 August to 25 August 2026. The inspection aimed to verify compliance with the Food, Drug and Cosmetic Act and related regulations governing pharmaceutical manufacturing.
Form 483 Observations Upon concluding the inspection, the USFDA issued a Form 483 to Cipla’s management, listing seven inspectional observations. Form 483 is a formal notice that highlights conditions the investigator believes may constitute violations of the FD&C Act. While the specific observations were not disclosed in the filing, their presence signals the FDA’s concern over certain manufacturing practices.
Cipla’s Response and Next Steps Cipla confirmed it will collaborate closely with the USFDA to address all seven observations. The company reiterated its commitment to remediate each issue within the time limits set by the regulator, underscoring its adherence to global quality standards. Investors and stakeholders are advised to monitor Cipla’s remediation progress as it may impact regulatory standing and market perception.
